Virginia Commonwealth University

VCU Scholars Compass
VCU Health Publications

VCU Health

2007

Peginterferon Alfa-2a and Ribavirin for 16 or 24
Weeks in HCV Genotype 2 or 3
Mitchell L. Shiffman
Virginia Commonwealth University

Fredy Suter
Ospedali Riuniti

Bruce R. Bacon
St Louis University
See next page for additional authors

Follow this and additional works at: http://scholarscompass.vcu.edu/vcuhealth_pubs
Part of the Medicine and Health Sciences Commons
From The New England Journal of Medicine, Shiffman, M. L., Suter, F., Bacon, B. R. et al., Peginterferon Alfa-2a and
Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3, Vol. 357, Page 124, Copyright © 2007 Massachusetts Medical
Society. Reprinted with permission.

Downloaded from
http://scholarscompass.vcu.edu/vcuhealth_pubs/17

This Article is brought to you for free and open access by the VCU Health at VCU Scholars Compass. It has been accepted for inclusion in VCU Health
Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.

Authors

Mitchell L. Shiffman, Fredy Suter, Bruce R. Bacon, David Nelson, Hugh Harley, Richard Sola, Stephen D.
Shafran, Karl Barange, Amy Lin, Ash Soman, and Stefan Zeuzem

This article is available at VCU Scholars Compass: http://scholarscompass.vcu.edu/vcuhealth_pubs/17

The

n e w e ng l a n d j o u r na l

of

m e dic i n e

original article

Peginterferon Alfa-2a and Ribavirin
for 16 or 24 Weeks in HCV Genotype 2 or 3
Mitchell L. Shiffman, M.D., Fredy Suter, M.D., Bruce R. Bacon, M.D.,
David Nelson, M.D., Hugh Harley, M.B., B.S., Ricard Solá, M.D.,
Stephen D. Shafran, M.D., Karl Barange, M.D., Amy Lin, M.S., Ash Soman, M.B., B.S.,
and Stefan Zeuzem, M.D., for the ACCELERATE Investigators*

A BS T R AC T
Background
From the Virginia Commonwealth Univer
sity Medical Center, Richmond (M.L.S.); Os
pedali Riuniti, Bergamo, Italy (F.S.); Saint
Louis University, St. Louis (B.R.B.); Uni
versity of Florida, Gainesville (D.N.);
Royal Adelaide Hospital, Adelaide, Aus
tralia (H.H.); Universitat Autònoma de
Barcelona, Barcelona (R.S.); University
of Alberta Hospital, Edmonton, Canada
(S.D.S.); Hôpital Purpan, Toulouse, France
(K.B.); Roche, Nutley, NJ (A.L.); Roche,
Welwyn, United Kingdom (A.S.); and Saar
land University Hospital, Homburg/Saar,
Germany (S.Z.). Address reprint requests
to Dr. Shiffman at the Liver Transplant
Program, Virginia Commonwealth Uni
versity Medical Center, 1251 E. Marshall
St., Box 663, Richmond, VA 23298, or at
mshiffma@vcu.edu.
*The investigators who participated in
the ACCELERATE trial are listed in the
Appendix.
N Engl J Med 2007;357:124-34.
Copyright © 2007 Massachusetts Medical Society.

Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin for 24 weeks. We conducted a large, randomized, multinational,
noninferiority trial to determine whether similar efficacy could be achieved with
only 16 weeks of treatment with peginterferon alfa-2a and ribavirin.
Methods

We randomly assigned 1469 patients with HCV genotype 2 or 3 to receive 180 μg of
peginterferon alfa-2a weekly, plus 800 mg of ribavirin daily, for either 16 or 24 weeks.
A sustained virologic response was defined as an undetectable serum HCV RNA level
(<50 IU per milliliter) 24 weeks after the end of treatment.
Results

The study failed to demonstrate that the 16-week regimen was noninferior to the
24-week regimen. The sustained virologic response rate was significantly lower in
patients treated for 16 weeks than in patients treated for 24 weeks (62% vs. 70%;
odds ratio for 16 weeks vs. 24 weeks, 0.67; 95% confidence interval, 0.54 to 0.84;
P<0.001). In addition, the rate of relapse (a detectable HCV RNA level during follow-up
in patients who had undetectable HCV RNA at the end of treatment) was significantly greater in the 16-week group (31%, vs. 18% in the 24-week group; P<0.001).
The sustained virologic response rates in patients with a pretreatment serum HCV
RNA level of 400,000 IU per milliliter or less was 82% with the 16-week regimen and
81% with the 24-week regimen. Among patients with a rapid virologic response (an
undetectable HCV RNA level by week 4), sustained virologic response rates were
79% in the 16-week group and 85% in the 24-week group (P = 0.02).
Conclusions

Treatment with peginterferon and ribavirin for 16 weeks in patients infected with
HCV genotype 2 or 3 results in a lower overall sustained virologic response rate
than treatment with the standard 24-week regimen. (ClinicalTrials.gov number,
NCT00077636.)
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T

he currently recommended treatment for patients infected with hepatitis C
virus (HCV) genotype 2 or 3 is peginterferon, plus 800 mg of ribavirin daily, for 24 weeks.1
Approximately 80% of patients have a sustained
virologic response with this regimen.2,3 This high
response rate has prompted studies of shorter
treatment durations. Sustained virologic response
rates of 80 to 85% were observed with just 12 to
16 weeks of treatment in patients whose HCV
RNA levels became undetectable within 4 weeks
after commencing treatment.4-7 These results suggest that patients with HCV genotype 2 or 3 who
have a rapid virologic response (an undetectable
HCV RNA level by week 4) could be treated for
less than 24 weeks. However, confirmation is
needed before a shortened treatment period can
be widely recommended for patients with HCV
genotype 2 or 3.8 In our large, randomized, multi
national study, we aimed to determine whether
similar efficacies could be achieved with 16 and
24 weeks of treatment with peginterferon alfa-2a
plus ribavirin in patients infected with HCV genotype 2 or 3.

vere psychiatric disease, had clinically significant
cardiovascular or renal disease, had an uncontrolled seizure disorder, had severe retinopathy,
or had previously received interferon or ribavirin.
Patients with cirrhosis had to have a Child–Pugh
score of less than 7 to be eligible.
Study Design

The study was conducted at 132 centers worldwide. All sites received approval from an appropriate institutional review board. The first patient
was enrolled in November 2003, and the last patient completed follow-up in September 2005. Each
patient provided written informed consent. Patients
were randomly assigned, in a 1:1 ratio, to receive
16 or 24 weeks of treatment with subcutaneous
peginterferon alfa-2a (Pegasys, Roche), 180 μg
once weekly, plus oral ribavirin (Copegus, Roche),
400 mg twice daily. The treatment period was
followed by a 24-week observation period. Patients
were randomly assigned in blocks of four and
were stratified according to HCV genotype and
country of residence. Assignment to treatment
duration was centralized, with the sponsor, investi
gators, and patients unaware of the assignment.
Treatment duration was double-blinded until week
Me thods
16, at which time investigators were informed by
The trial was designed by the sponsor and the telephone of their patients’ assignments.
principal academic investigators. The data were
collected by Covance Central Laboratory Services Efficacy Assessments
and were managed by the sponsor and the aca- Serum HCV RNA levels were measured with the
demic investigators. The sponsor performed the use of a qualitative polymerase-chain-reaction
statistical analysis. The academic investigators assay (Cobas Amplicor HCV Test, version 2.0; dewere responsible for the decision to publish the tection limit, 50 IU per milliliter) at weeks 4, 12,
results and had unrestricted access to the data. and 16 or 24 during the treatment phase and at
An academic author wrote or edited all sections weeks 12 and 24 of follow-up. The primary end
of the manuscript. One academic author (Dr. Shiff point was sustained virologic response, defined as
man) and one industry author (Ms. Lin) vouch for an undetectable serum HCV RNA level at 24 weeks
the completeness and accuracy of the data.
after the end of treatment. A rapid virologic response was defined as an undetectable serum
Selection of Patients
HCV RNA level by week 4 of treatment. Virologic
Eligible patients were those who were 18 years of relapse was defined as a detectable HCV RNA
age or older, were infected with HCV genotype 2 level during follow-up in patients who had had
or 3 (as determined with the use of the INNO-LiPA undetectable HCV RNA at the end of treatment.
assay, Innogenetics), and had a quantifiable serum HCV RNA level (>600 IU per milliliter), an Safety Assessments
elevated serum alanine transaminase level, and Safety was assessed by means of physical examifindings on liver biopsy consistent with chronic nations and laboratory tests at weeks 2, 4, 8, 12,
HCV infection. Patients were ineligible if they had and 16 in both groups and at weeks 20 and 24 in
other liver diseases, were infected with the hu- the 24-week group (all during the treatment peman immunodeficiency virus, had hepatocellular riod), as well as at weeks 4, 12, and 24 of the
carcinoma, had severe depression or another se- follow-up period in both groups. Stepwise reducn engl j med 357;2
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1810 Patients were screened

341 Were not randomly assigned because they
failed to meet inclusion criteria or were
otherwise unwilling or unable to participate

1469 Were randomly assigned
to treatment

736 Received 180 µg of peginterferon
alfa-2a once weekly+800 mg
of ribavirin daily for 16 wk

733 Received 180 µg of peginterferon
alfa-2a once weekly+800 mg
of ribavirin daily for 24 wk

3 Never took any study medication

1 Never took any study medication

733 (>99%) Received at least
one dose

732 (>99%) Received at least
one dose

732 Were in the intentionto-treat population
1 Was excluded because
original case report form
was unavailable

41 Were withdrawn
17 Had an adverse event
3 Had an abnormal laboratory-test result
8 Refused treatment
3 Were withdrawn for
administrative or
other reasons
10 Were lost to follow-up

731 Were in the intentionto-treat population
1 Was excluded because
original case report form
was unavailable

715 (97%) Completed 8 wk
of treatment

714 (97%) Completed 8 wk
of treatment

692 (94%) Completed 16 wk
of treatment

685 (93%) Completed 16 wk
of treatment

39p6 24 wk
641 (87%) Completed
of treatment

690 (94%) Completed 12 wk
of follow-up

666 (91%) Completed 12 wk
of follow-up

667 (91%) Completed 24 wk
of follow-up

652 (89%) Completed 24 wk
of follow-up

91 Were withdrawn
34 Had an adverse event
2 Had an abnormal laboratory-test result
31 Refused treatment
2 Were withdrawn for
administrative or
other reasons
18 Were lost to follow-up
2 Violated an eligibility
criterion
2 Withdrew

Figure 1. Study Enrollment and Disposition of Patients.
RETAKE
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Table 1. Pretreatment Characteristics of the Patients.*
Characteristic

16 Wk of Peginterferon Alfa-2a + Ribavirin

24 Wk of Peginterferon Alfa-2a + Ribavirin

Genotype 2
(N = 372)

Genotype 3
(N = 358)

Any Genotype
(N = 732)†

Genotype 2
(N = 356)

Genotype 3
(N = 369)

Any Genotype
(N = 731)‡

224 (60)

224 (63)

448 (61)

213 (60)

243 (66)

461 (63)

Sex — no. (%)
Male

148 (40)

134 (37)

284 (39)

143 (40)

126 (34)

270 (37)

Age — yr

Female

49.5±9.2

42.4±9.0

46.0±9.8

49.3±9.3

42.1±9.4

45.6±10.0

Weight — kg

84.2±19.8

78.9±18.1

81.5±19.2

84.3±19.3

79.1±17.5

81.6±18.6

Body-mass index

28.7±5.8

26.8±5.5

27.8±5.7

28.7±5.8

26.6±5.1

27.6±5.6

White

309 (83)

325 (91)

635 (87)

301 (85)

333 (90)

638 (87)

Black

12 (3)

10 (3)

22 (3)

18 (5)

3 (<1)

21 (3)

Asian

11 (3)

9 (3)

21 (3)

8 (2)

8 (2)

18 (2)

Other

40 (11)

14 (4)

54 (7)

29 (8)

25 (7)

54 (7)

Race or ethnic group — no. (%)

Serum HCV RNA level
Mean ±SD — log IU/ml

6.38±0.85

6.15±0.88

6.27±0.87

6.40±0.87

6.15±0.80

6.27±0.85

≤400,000 IU/ml — no. (%)

63 (17)

97 (27)

160 (22)

55 (15)

91 (25)

147 (20)

>400,000–800,000 IU/ml — no. (%)

19 (5)

45 (13)

64 (9)

34 (10)

46 (12)

81 (11)

>800,000 IU/ml — no. (%)

290 (78)

216 (60)

508 (69)

267 (75)

232 (63)

503 (69)

103 (28)

81 (23)

185 (25)

90 (25)

75 (20)

165 (23)

97 (26)

50 (14)

147 (20)

98 (28)

58 (16)

157 (21)

>0–5% of hepatocytes

101 (27)

90 (25)

191 (26)

94 (26)

85 (23)

181 (25)

6–33% of hepatocytes

30 (8)

58 (16)

88 (12)

22 (6)

66 (18)

89 (12)

34–66% of hepatocytes

11 (3)

41 (11)

53 (7)

13 (4)

39 (11)

52 (7)

10 (3)

13 (2)

109 (30)

240 (33)

Bridging fibrosis or cirrhosis — no. (%)
Steatosis — no. (%)
None

>66% of hepatocytes
Unknown

3 (<1)
130 (35)

0
129 (36)

4 (1)
117 (32)

4 (<1)
248 (34)

* Plus–minus values are means ±SD. Data are from the intention-to-treat population (all patients who received at least one dose of study
medication). The body-mass index is the weight in kilograms divided by the square of the height in meters. Race or ethnic group was selfreported. Liver biopsy was performed within 24 months before the start of the study, and specimens were assessed by local pathologists for
histologic status and were reviewed by one central pathologist, who was unaware of group assignment, for steatosis. Pretreatment assess
ments of liver steatosis were available for only approximately two thirds of patients. Steatosis was defined on the basis of the percentage of
hepatocytes with fatty changes in one low-power field. The presence or absence of bridging fibrosis or cirrhosis could not be determined for
one patient in the 24-week group.
† In addition to patients with HCV genotype 2 or 3 monoinfection, the overall group receiving treatment for 16 weeks included two patients
infected with both HCV genotypes 2 and 4.
‡ In addition to patients with HCV genotype 2 or 3 monoinfection, the overall group receiving treatment for 24 weeks included four patients
infected with both HCV genotypes 2 and 4, one with HCV genotype 1 only, and one with both HCV genotypes 1 and 2.

tions in the dose of peginterferon alfa-2a to 135 μg
per week and then to 90 μg per week, and stepwise reductions in the dose of ribavirin to 600 mg
per day, were permitted, to manage clinically significant adverse events or laboratory abnormalities. Restoration of the initial doses was permitted
at the discretion of the investigator if the adverse

n engl j med 357;2

event or laboratory abnormality improved or resolved. Patients could receive peginterferon alfa-2a
alone if ribavirin was stopped, but study treatment
was discontinued if peginterferon alfa-2a was
stopped. The use of granulocyte colony-stimulating factor and erythropoietin was permitted but
not encouraged.
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A Per-Protocol Analysis
16 Wk

Sustained Virologic Response
(% of patients)

100
90
80

P<0.001
P<0.001

70
60
50

24 Wk

P=0.16
82

76
65

65

65

71

40
30
20
10
0

Any HCV Genotype

HCV Genotype 2

HCV Genotype 3

B Modified Intention-to-Treat Analysis
16 Wk

24 Wk

Sustained Virologic Response
(% of patients)

100
90
80

P<0.001

P<0.001

P=0.23

70
50

75

70

60
62

62

62

66

40
30
20
10
0

Any HCV Genotype

HCV Genotype 2

HCV Genotype 3

Figure 2. Rates of Sustained Virologic Response in Patients Randomly
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The primary analysis was based on data from the
per-protocol population, according to guidelines
of the International Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use, because it is
considered to be more a conservative means of
analysis in a noninferiority trial. A modified
intention-to-treat analysis was also performed, because it is considered to be a more stringent means
of measuring overall efficacy and tolerability and
it includes data from all patients who were randomly assigned to a treatment group and who
received at least one dose of study medication.
Moreover, when intention-to-treat and per-proto128
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col analyses lead to essentially the same conclusions, confidence in the trial results is increased.
Patients for whom HCV RNA levels had not been
measured by the end of the follow-up period were
considered to have had treatment failure.
Our primary objective was to show that treatment for 16 weeks was no worse than treatment
for 24 weeks, as defined by a noninferiority margin of 6%. Response rates at the end of the treatment period and sustained virologic response
rates in the two treatment groups were compared
with the use of the Cochran–Mantel–Haenszel
test (after data were stratified according to country of residence and HCV genotype). The common
odds ratios and 95% confidence intervals were
estimated. The interaction of treatment group
and HCV genotype was assessed with the use of
the Breslow–Day test, with data stratified according to genotype. The noninferiority margin was
converted from 6% to an odds ratio of 0.70 by
assuming a sustained virologic response rate of
80% in the 24-week group. On this basis, the 16week and 24-week regimens would be considered
equivalent if the lower limit of the 95% confidence interval for the odds ratio was at least 0.70.
The planned enrollment of 700 patients per treatment group assumed a sustained virologic response rate of 80% in both groups, a statistical
power of the study of 80%, and a two-sided significance level of 0.05.
The safety analysis included data from all treat
ed patients who underwent safety evaluations dur
ing the treatment period. Stepwise, backward,
and multiple logistic-regression analyses were
used to examine the effect of treatment duration
and pretreatment factors on the sustained virologic response. There was evidence of an interaction between treatment group and genotype
(P = 0.06), so separate analyses were performed
according to genotype. The Cochran–Mantel–
Haenszel test was conducted on data stratified
on the basis of country of residence. Data were
not stratified for other subgroup analyses. P values were two-sided and were not adjusted for
multiple testing.

R e sult s
Of 1810 patients screened, 1469 were randomly
assigned to a treatment group and 1465 received
at least one dose of medication (Fig. 1). The two
treatment groups were well matched (Table 1).
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Figure 3. Virologic Response Rates during the Treatment
and Follow-up Periods in Patients Randomly Assigned
to Receive Treatment for 16 or 24 Weeks.
A rapid virologic response was defined as an undetect
able serum HCV RNA level (<50 IU per milliliter) by
week 4. An early virologic response was defined as an
undetectable HCV RNA level, or a decrease in the HCV
RNA level by more than 2 log10 units from the pretreat
ment value, by week 12. A sustained virologic response
was defined as an undetectable serum HCV RNA level
at 24 weeks after the end of treatment. The overall data
for sustained virologic response are given for patients
infected with only HCV genotype 2 or 3 plus two pa
tients with both HCV genotypes 2 and 4 in the 16-week
group and four patients with both HCV genotypes 2
and 4, one with HCV genotype 1 only, and one with
both HCV genotypes 1 and 2 in the 24-week group.

Wk

16-Wk Group

24-Wk Group

Rapid virologic response rate, 67%
Genotype 2, 69% (257/372)
Genotype 3, 64% (230/358)

Rapid virologic response rate, 64%
Genotype 2, 69% (247/356)
Genotype 3, 59% (219/369)

12

Early virologic response rate, 89%
Genotype 2, 91% (338/372)
Genotype 3, 87% (312/358)

Early virologic response rate, 89%
Genotype 2, 94% (333/356)
Genotype 3, 85% (314/369)

16

Virologic response rate at end
of treatment, 89%
Genotype 2, 90% (335/372)
Genotype 3, 89% (317/358)

0

4

8

Virologic Response

The results failed to show noninferiority of the
16-week regimen relative to the 24-week regimen in
both the per-protocol and the modified intentionto-treat analyses. Indeed, both analyses showed a
similar pattern in the sustained virologic response
rate among all patients, which was significantly
lower in patients treated for 16 weeks than in
those treated for 24 weeks in the per-protocol
analysis (65% vs. 76%; odds ratio for 16 weeks
vs. 24 weeks, 0.59; 95% confidence interval [CI],
0.46 to 0.76; P<0.001) (Fig. 2A) and in the modified intention-to-treat analysis (62% vs. 70%;
odds ratio, 0.67; 95% CI, 0.54 to 0.84; P<0.001)
(Fig. 2B). All subsequent analyses were done on
data from the modified intention-to-treat population.
The virologic response rate at the end of the
treatment period was significantly higher in the
16-week group than in the 24-week group (odds
ratio for 16 weeks vs. 24 weeks, 1.82; 95% CI, 1.35
to 2.47), because more patients in the 24-week
group were withdrawn prematurely and were con
sidered not to have had a response. Thus, the sig
nificant difference in the sustained virologic response rate reflects a significantly higher relapse
rate in the 16-week group (31%; 95% CI, 27 to 34)
than in the 24-week group (18%; 95% CI, 15 to
21; P<0.001) (Fig. 3).
Patients infected with HCV genotype 2 had
higher virologic response rates at the end of treatment and at the end of follow-up than did patients with HCV genotype 3 (Fig. 3). Within each
genotype group, relapse rates were significantly
higher among patients treated for 16 weeks than

20

Virologic response rate at end
of treatment, 82%
Genotype 2, 84% (299/356)
Genotype 3, 80% (296/369)

24

28

32

36

40

Sustained virologic response
rate, 62% (455/732)
Genotype 2, 62% (232/372)
Genotype 3, 62% (221/358)

44

Sustained virologic response
rate, 70% (515/731)
Genotype 2, 75% (268/356)
Genotype 3, 66% (244/369)

48
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among those treated for 24 weeks (for genotype 2,
30% vs. 15%; for genotype 3, 31% vs. 22%; P<0.001
for both comparisons).
Predictors of Sustained Virologic Response

Prespecified stepwise, backward, and multiple
logistic-regression analyses showed that several
factors were predictive of sustained virologic response: HCV genotype (odds ratio among patients
with genotype 2 vs. genotype 3, 1.88; 95% CI,
1.46 to 2.43; P<0.001); pretreatment HCV RNA
level (odds ratio for ≤400,000 IU per milliliter vs.
>800,000 IU per milliliter, 3.01; 95% CI, 2.15 to
4.20; P<0.001; and odds ratio for >400,000 to
800,000 IU per milliliter vs. >800,000 IU per milliliter, 1.64; 95% CI, 1.10 to 2.46; P = 0.02); age
(odds ratio for ≤45 years vs. >45 years, 1.50; 95%
CI, 1.17 to 1.93; P = 0.002); weight (odds ratio for
≤80 kg vs. >80 kg, 1.75; 95% CI, 1.37 to 2.24;
P<0.001), alanine aminotransferase quotient (the
patient’s alanine aminotransferase value divided
by the upper limit of the normal range) (odds
ratio for >3 vs. ≤3, 1.47; 95% CI, 1.14 to 1.90;
P = 0.003); bridging fibrosis or cirrhosis (odds ratio
for absence vs. presence, 2.15; 95% CI, 1.63 to
2.81; P<0.001), and treatment duration (odds ratio
for 24 weeks vs. 16 weeks, 1.56; 95% CI, 1.24 to
1.97; P < 0.001).
Lower pretreatment HCV RNA level, lower
weight, and absence of bridging fibrosis or cirrhosis were predictive of a sustained virologic
response in separate analyses performed for patients with HCV genotype 2 and those with HCV
genotype 3 (P<0.01 for all analyses). Treatment
for 24 weeks predicted a sustained virologic
response in patients infected with genotype 2
(P<0.001) but not in those infected with genotype 3 (P = 0.12).
Subgroup Analyses

Subgroup analyses indicated that, with the possible exception of genotype, interactions between
treatment duration and various factors were not
significant (Fig. 4). The sustained virologic response rate was higher in patients with HCV
genotype 2 and those with HCV genotype 3 treated for 24 weeks than in corresponding patients
treated for 16 weeks, but the difference was significant only for patients with genotype 2.
A rapid virologic response was achieved in 67%
of patients in the 16-week group and in 64% of

130
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Figure 4 (facing page). Effect of Characteristics of Patients,
before and during Treatment, on Sustained Virologic
Response.
A sustained virologic response was defined as an un
detectable serum HCV RNA level (<50 IU per milliliter)
at 24 weeks after the end of treatment. Steatosis was
defined as more than 5% of hepatocytes with fatty
changes in one low-power field. A rapid virologic re
sponse was defined as an undetectable serum HCV
RNA level by week 4 of treatment. The shaded area in
dicates odds ratios of at least 0.70, the noninferiority
margin, showing that the 16-week group is at least as
effective as the 24-week group. In addition to patients
infected with HCV genotype 2 or 3, for the “all patients”
and “any genotype” categories, the 16-week group in
cluded two patients with HCV genotypes 2 and 4, and
the 24-week group included four patients with HCV
genotypes 2 and 4, one with HCV genotype 1, and one
with HCV genotypes 1 and 2. Pretreatment assessments
of liver steatosis were available for only approximately
two thirds of patients. The presence or absence of cir
rhosis or bridging fibrosis could not be determined for
one patient in the 24-week group.

patients in the 24-week group. Among the patients
with a rapid virologic response, sustained virologic response rates were consistently higher in
the 24-week group than in the 16-week group,
both overall (85% vs. 79%, P = 0.02) and within
each genotype group (Fig. 5A). Sustained virologic response rates were considerably lower among
patients without a rapid virologic response than
among those with a rapid response, and among
those without a rapid response, sustained virologic response rates were consistently higher in
the 24-week group than in the 16-week group
(Fig. 5B).
Safety

The most common cause of dose modifications
of peginterferon alfa-2a and ribavirin were neutropenia and anemia, respectively. The percentage
of patients who had their dose of peginterferon
alfa-2a reduced because of adverse events or laboratory abnormalities was similar in the 24-week
group and the 16-week group (17% and 14%, respectively). In contrast, a higher percentage of
patients in the 24-week group than in the 16week group had their dose of ribavirin reduced
(23% vs. 17%, P = 0.01).
The percentage of patients reporting adverse
events or serious adverse events was similar in the
two groups. The adverse events reported were
those typical of interferon-based treatment, in-
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Group

Sustained Virologic Response
16 Wk

All patients
HCV genotype
2
3
Pretreatment HCV RNA level
Any genotype
≤400,000 IU/ml
>400,000–800,000 IU/ml
>800,000 IU/ml
Genotype 2
≤400,000 IU/ml
>400,000–800,000 IU/ml
>800,000 IU/ml
Genotype 3
≤400,000 IU/ml
>400,000–800,000 IU/ml
>800,000 IU/ml
Cirrhosis or bridging fibrosis
pretreatment
Any genotype
No
Yes
Genotype 2
No
Yes
Genotype 3
No
Yes
Liver steatosis at baseline
Any genotype
No
Yes
Genotype 2
No
Yes
Genotype 3
No
Yes
Rapid virologic response
Any genotype
Yes
No
Genotype 2
Yes
No
Genotype 3
Yes
No

Odds Ratio for 16-Wk Group

Hazard Ratio for
Event (95% CI)

P Value for
Interaction

Difference between
16 and 24 Wk

24 Wk

no./total no. (%)

% (95% CI)

455/732 (62) 515/731 (70)

−8 (−13 to −3)

232/372 (62) 268/356 (75)
221/358 (62) 244/369 (66)

−13 (−20 to −6)
−4 (−11 to 3)

0.53 (0.39–0.74)
0.83 (0.61–1.12)

132/161 (82) 122/150 (81)
43/65 (66)
59/80 (74)
280/506 (55) 334/501 (67)

1 (−8 to 9)
−8 (−23 to 7)
−11 (−17 to −5)

1.04 (0.59–1.86)
0.70 (0.34–1.42)
0.62 (0.48–0.80)

52/63 (83)
45/55 (82)
13/19 (68)
27/34 (79)
167/290 (58) 196/267 (73)

1 (−13 to 15)
−11 (−36 to 14)
−16 (−24 to −8)

1.05 (0.41–2.70)
0.56 (0.16–2.01)
0.49 (0.34–0.70)

79/97 (81)
74/91 (81)
29/45 (64)
32/46 (70)
113/216 (52) 138/232 (59)

0 (−11 to 11)
−5 (−24 to 14)
−7 (−16 to 2)

1.01 (0.48–2.10)
0.79 (0.33–1.90)
0.75 (0.51–1.09)

367/547 (67) 420/566 (74)
88/185 (48) 95/165 (58)

−7 (−12 to −2)
−10 (−20 to 0)

0.71 (0.55–0.92)
0.67 (0.44–1.02)

180/269 (67) 210/266 (79)
52/103 (50)
58/90 (64)

−12 (−19 to −5)
−14 (−28 to 0)

0.54 (0.37–0.80)
0.56 (0.32–1.00)

186/277 (67) 207/294 (70)
35/81 (43)
37/75 (49)

−3 (−11 to 4)
−6 (−22 to 10)

0.86 (0.60–1.22)
0.78 (0.42–1.47)

220/338 (65) 255/338 (75)
83/154 (54) 87/145 (60)

−10 (−17 to −4)
−6 (−17 to 5)

0.61 (0.43–0.85)
0.78 (0.49–1.23)

129/198 (65) 151/192 (79)
24/44 (55)
27/35 (77)

−13 (−22 to −5)
−23 (−43 to −2)

0.51 (0.32–0.80)
0.36 (0.13–0.95)

91/140 (65) 102/143 (71)
58/109 (53) 60/109 (55)

−6 (−17 to 5)
−2 (−15 to 11)

0.75 (0.45–1.23)
0.93 (0.55–1.58)

387/489 (79) 400/470 (85)
58/220 (26) 110/247 (45)

−6 (−11 to −1)
−18 (−27 to −10)

0.66 (0.48–0.93)
0.45 (0.30–0.66)

200/257 (78) 210/247 (85)
27/103 (26) 53/100 (53)

−7 (−14 to 0)
−27 (−40 to −14)

0.62 (0.39–0.98)
0.32 (0.17–0.57)

185/230 (80) 187/219 (85)
31/117 (26) 57/145 (39)

−5 (−12 to 2)
−13 (−24 to −2)

0.70 (0.43–1.16)
0.56 (0.33–0.94)

0.06

0.26

0.33

0.78

0.82

0.91

0.80

0.39

0.52

0.56

0.13

0.08

0.53
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13 patients (2%) treated for 16 weeks and in 20
patients (3%) treated for 24 weeks. Severe anemia
(defined as a hemoglobin level of <8.5 g per deciliter) developed in four patients (<1%) in each
group. Nearly all patients (97% of those in the
16-week group and 99% of those in the 24-week
group) had at least one adverse event.
The percentage of patients withdrawn from the

Overall,
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study during the first 16 weeks of therapy was
similar in the two groups (Fig. 1). Overall, 4% of
patients in the 16-week group and 5% of patients
in the 24-week group were withdrawn because
of adverse events or laboratory abnormalities.

A Patients with a Rapid Virologic Response at Wk 4
16 Wk

of
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Our large, randomized study of patients infected
with HCV genotype 2 or 3 shows that a fixed 16week regimen of peginterferon alfa-2a plus ribavirin results in significantly lower sustained virologic response rates than does a fixed 24-week
regimen. Consistent with the overall result, the
odds ratios for a sustained virologic response favored 24 weeks of treatment over 16 weeks in
many subgroups, a finding that suggests that the
preferred initial duration of treatment for patients
with genotype 2 or 3 should continue to be 24
weeks.
The results of several small studies suggest
that treatment with pegylated interferon and riba
virin for 12 or 16 weeks, rather than 24 weeks,
does not adversely affect sustained virologic response rates in patients with HCV genotype 2 or
3.4-6 In two such studies,5,6 patients treated for 24
weeks had somewhat lower virologic response
rates at the end of the treatment period than did
those receiving shorter regimens, presumably be
cause of higher dropout rates with longer treatment. In contrast, relapse rates were somewhat
higher with the shorter duration of treatment.
As a result, the higher dropout rates in the 24week treatment groups were offset by the higher
relapse rates in the shorter-treatment groups,
resulting in the groups having similar sustained
virologic response rates. This finding led many
to conclude that a shorter regimen is as effective
as the standard 24-week regimen. The intentionto-treat analysis of our data reveals the same
pattern: higher dropout rates in the 24-week group
and higher relapse rates in the 16-week group.
Response rates at the end of the treatment period were similar (within 3%; data not shown) in
the two groups, according to the per-protocol
analysis. This similarity, in addition to our large
sample size, shows that reducing the treatment
duration from 24 to 16 weeks results in increased
relapse rates and therefore reduced sustained
virologic response rates.
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The customization of the duration of therapy
is an emerging theme in the management of
chronic HCV.5,9-11 In patients infected with genotype 2 or 3, a variable treatment regimen (12
weeks in patients with a rapid virologic response
and 24 weeks in those without a rapid virologic
response) resulted in a sustained virologic response
rate (77%) similar to that from a standard 24week regimen (76%).5 Our study was not designed
to evaluate this treatment approach, but our results shed light on its validity. Overall, 66% of
patients with HCV genotype 2 or 3 had rapid virologic responses in our study, a figure similar
to that found by Mangia et al. (63%).5 The sustained virologic response rate among patients
with a rapid virologic response treated for 16
weeks and those without a rapid virologic response treated for 24 weeks — a population sim
ilar to the variable-duration group in the study
by Mangia et al. — was 68%, similar to the 70%
rate in our fixed 24-week group. A variable-duration treatment strategy may therefore be as effective as a fixed-duration strategy and may be less
expensive for and better tolerated by the majority
of patients. The trade-off in reducing the treatment duration is an increased relapse rate, which
was observed in our study and in other studies.4‑6
Thus, the reduction of the treatment duration,
even in patients with rapid virologic responses, is
likely to be accompanied by higher relapse rates
and the need to consider retreatment for these
patients.
Could higher doses of ribavirin prevent relapse
after treatment for less than 24 weeks? In previous studies, treatment for 24 weeks with ribavirin
(with the dose based on body weight) provided
no benefit over the recommended ribavirin dose
of 800 mg per day in patients infected with HCV
genotype 2 or 3.2,12 In fact, one study13 has suggested that it may be possible to reduce the ribavirin dose to 400 mg per day without compromising the efficacy of the standard 24-week
regimen. Ribavirin doses as high as 1200 mg per
day, which have been used in studies evaluating
reduced durations of therapy,5-7 appear to offer
no obvious benefit in reducing the relapse rate.
However, further study is needed to confirm the
optimal dose of ribavirin for abbreviated treatment regimens.
Sustained virologic response rates decrease in

n engl j med 357;2

inverse proportion to pretreatment viral load.2,3,14
Among patients with a pretreatment viral load of
400,000 IU per milliliter or less in our study, the
sustained virologic response rate was 1% higher
in the 16-week group than in the 24-week group.
Among those with a pretreatment viral load of
more than 400,000 IU per milliliter, the difference was 11%, in favor of the 24-week regimen.
Patients with low pretreatment viral loads or rapid
virologic responses have the highest likelihood
(>78%) of a sustained virologic response with 16
weeks of therapy. Reduced durations of therapy
may also be reasonable in patients who have adverse events and are unlikely to tolerate 24 weeks
of therapy. The decision to reduce the duration of
treatment must be balanced against the increased
risk of relapse. Patients who do not have a rapid
virologic response should not be considered easy
to cure and should not be offered abbreviated
treatment.
In conclusion, our study shows that a fixed
16-week regimen is inferior to a fixed 24-week
regimen in patients with HCV genotype 2 or 3.
These patients should not be routinely treated for
less than the currently recommended 24 weeks.
However, patients with a low pretreatment viral
load or a rapid virologic response appear to have
the highest probability of having a sustained response with 16 weeks of therapy, and such therapy may be a reasonable option for these patients.
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